CMA mounting a big enquiry, will that impact the price of veterinary drugs in general including wholesale? |
A monthly close above 229.5p and there is a chance it runs a while, no doubt some set backs along the way, but likely heading a decent amount higher thereafter. Dyor etc. |
Need more Vets to increase competition and that should also increase demand for AnimalCare products. |
More to do with Vets services and practices I believe. |
Will the CMA enquiry cause them any trouble if they've to reduce their product prices? |
Was buying this whilst no one else was interested. Should have bought more. Can become a lovely little business spinning off cash and with some growth thrown in - assuming they allocate the cash wisely, which I think they will. CEO seems sensible. |
If we were lucky enough to close the month over about 229.5p the complexion would change considerably. Perhaps a pullback afterwards but then march onwards and upwards imho. Dyor etc. |
There's always the risk the capital isn't allocated wisely but the CEO appears sensible overall with a keen focus on cash conversion and stable growth. My target (I don't have a timescale) is £4+. Dyor etc, I'm often wrong.
Do suspect they have some targets for the cash lined-up. |
From the latest preliminary financial update: "The Group ended the financial year in a net cash position, pre IFRS16 leases, of £1.7 million, (31 December 2022: £2.4 million debt). This very strong financial platform enables the pursuit of inorganic and organic opportunities that support the Group's long-term growth strategy."
Today after Identicare sale: "........cash consideration of £24.9m (the "Consideration") payable upon completion of this sale........Upon receipt of the Consideration and after fees associated with the transaction, the Company's net cash is expected to be around £27.0m."
About £116M market cap with net cash of £27M and £74.4M revenue last year with strong cash conversion, lose about £3M revenue from Identicare (haven't checked if profit contribution, certainly was growing & probably a decent margin).
Now more focussed. See if it garners interest in the next few weeks prior to results on 9th April.
Still a lovely and quiet PBB. |
Excellent if they use the money wisely, |
Indenticare disposal and now a stronger balance sheet loaded up with cash.
I wasn't expecting a change this quickly.
Good news overall and now focus on core business growth.
"Jenny Winter, Chief Executive Officer commented: "I'm very proud to see what we have achieved with Identicare in recent years. Today's decision to crystallise the value from the sale is the logical next step, significantly strengthening our balance sheet and giving us additional financial flexibility and firepower as we concentrate on growing our pharmaceutical-focused animal health business."" |
May pullback but looking like a breakout and still lovely and quiet. |
May not be this week but getting there. |
Slowly moving, weekly close above 189p then a new phase imho, dyor etc. |
Lovely and quiet here, just how I like it. |
With some developments on the consumer side this could really show some growth.
CEO appears to be very capable.
More I dig tge more I quite like the potential, steady growth and now no bet debt. Dyor etc, I'm often wrong. |
TU confirms now net cash, turned a corner, ready for next stage of development.
Patience needed but looking decent. |
I see a much brighter future here than many might think, dyor though as I'm often wrong. Have been delving into this and taken a position recently as a wait and hold. Good little UK company, we need more like this. |
ANCR has some interesting hallmarks and looks relatively unloved. Sentiment can change with improved results. |
Looking firm today. Someone had to pay 246 for 23k when spread 215/230. Now you can sell 10k at 235p when spread 225/235. Go figure! |
 From WealthOracleAM....
Animalcare Limited founded in 1988 became the Animalcare Group in 2008. In July 2017 they made a reverse acquisition of Ecuphar NV, which is still casting a shadow over the share, as the share remains belowthe price before the transaction. Currently they are operating in 32 markets through 220 employees. ANCR is adopting a more organic approach towards growth, with focus on key therapy areas and new products development. This can be seen also in the financials with goodwill relatively flat over the years, but at quite high percentage of total assets – 51%, which has been impaired recently.
Other than the “underappreciated” by investors investment in 2017, the Group has been performing rather well. They have reduced their debt and increasing the cash generated from operations, thus gearing is minuscule at 16%. Revenue is growing at 39.1% CAGR, ROCE at 4.52% and dividends were doubled in 2020 from 2019, so there is plenty of return for the investors. However, ANCR remains very highly priced, with P/S just below the industry average and EV/EBITDA being quite high at 25.09. |
It is 23% of the company and the placing price is where the share price was 6 weeks ago so the discount is not that surprising.
It’s clear that Cardon has been wanting to move onto other things since he gave up being CEO in 2018 and then moved to non exec in 2019.
At least the overhang is gone now. |
Secondary placing - Hit share price very hard. Views?
8 July 2021. Animalcare Group plc (AIM: ANCR), the international animal health business, announces that it has been notified by Ecuphar Invest NV ("Seller") of its intention to sell up to 13,857,213 ordinary shares in the capital of the Company (the "Placing" and the "Placing Shares") at a price of 285 pence per Placing Share ("Placing Price"). The Placing Price represents a c. 20 per cent. discount to the closing price of 356 pence per share on 7 July 2021 |
Nice uplift since I bought during the first week of May. Our vet uses ANCR products:when i mentioned the imminent release of a new product, the vet was very interested . Suppliers of products to vets are onto a good thing. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
